Current state and practice variation in the use of Meningitis/Encephalitis (ME) FilmArray panel in children

Prabi Rajbhandari¹, Nathaniel Goodrich*², Aleisha M. Nabower², Miraides F. Brown¹, Maheswari Ekambaram³, Jaclyn Eisenberg⁴, Michael L. Forbes¹, Nathan Gollehon², Kimberly C. Martin⁵, Russell McCulloh³, Bryan Stone⁶, Matt Tandy⁵ and Jessica Snowden⁷

Abstract

**Background** The Meningitis/Encephalitis FilmArray® Panel (ME panel) was approved by the U.S. Food and Drug Administration in 2015 and provides rapid results when assessing patients with suspected meningitis or encephalitis. These patients are evaluated by various subspecialties including pediatric hospital medicine (PHM), pediatric emergency medicine (PEM), pediatric infectious diseases, and pediatric intensive care unit (PICU) physicians. The objective of this study was to evaluate the current use of the ME panel and describe the provider and subspecialty practice variation.

**Methods** We conducted an online cross-sectional survey via the American Academy of Pediatrics Section of Hospital Medicine (AAP-SOHM) ListServe, Brown University PEM ListServe, and PICU Virtual pediatric system (VPS) Listserve.

**Results** A total of 335 participants out of an estimated 6998 ListServe subscribers responded to the survey. 68% reported currently using the ME panel at their institutions. Among test users, most reported not having institutional guidelines on test indications (75%) or interpretation (76%). 58% of providers self-reported lack of knowledge of the test’s performance characteristics. Providers from institutions that have established guidelines reported higher knowledge compared to those that did not (51% vs. 38%; p = 0.01). More PHM providers reported awareness of ME panel performance characteristics compared to PEM physicians (48% vs. 27%; p = 0.004); confidence in test interpretation was similar between both groups (72 vs. 69%; p = 0.80).

**Conclusion** Despite the widespread use of the ME panel, few providers report having institutional guidelines on test indications or interpretation. There is an opportunity to provide knowledge and guidance about the ME panel among various pediatric subspecialties.

*Correspondence: Nathaniel Goodrich ngoodric@unmc.edu
1 Akron Children’s Hospital, One Perkins Square, Akron, OH, USA
2 University of Nebraska Medical Center, Omaha, NE, USA
3 Baylor Scott & White Medical Center, 300 University Blvd, Round Rock, TX, USA
4 The University of Chicago Medicine, 5841 S. Maryland Avenue, Chicago, IL, USA
5 University of Oklahoma-Tulsa School of Community Medicine, Tulsa, OK, USA
6 University of Utah Health, S John Medical Drive, Salt Lake City, UT, USA
7 University of Arkansas for Medical Sciences Little Rock, Arkansas, USA

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Pediatric meningitis and encephalitis (ME) are serious illnesses with significant morbidity and mortality including long-term sequelae with considerable economic burden [1, 2]. In October 2015, the United States (U.S.) Food and Drug Administration approved the Meningitis/Encephalitis FilmArray® Panel (ME panel), a test that offers rapid results compared to cerebrospinal fluid (CSF) culture for evaluation of suspected pediatric meningitis or encephalitis [3]. The test was developed by BioFire® [4] Diagnostics (Salt Lake City, Utah) and is a qualitative multiplex polymerase chain reaction (PCR) test used on the Film Array system. The ME panel detects 14 pathogens in the CSF: Escherichia coli K1, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus agalactiae (group B streptococcus or GBS), Streptococcus pneumoniae, Cytomegalovirus (CMV), Enterovirus, Epstein-Barr virus (EBV), Herpes simplex virus types 1 and 2 (HSV1 and HSV2), Human Herpes virus 6 (HHV6), Varicella zoster virus (VZV), Human parechovirus, and Cryptococcus neoformans/gatti. ME panel sensitivities vary by molecular target, with pediatric studies demonstrating sensitivities of 84–96% and specificities of >98% for the ME panel relative to the gold standard CSF cultures or standalone PCR testing [5–7]. The ME panel is also regarded as a more sensitive test than culture if the patient has been pre-treated with antibiotics prior to CSF collection [7, 8].

Clinical management of suspected meningitis/encephalitis depends on the specific pathogens causing illness and ranges from supportive care to a prolonged intensive care unit (ICU) stay and antimicrobial therapy [9–11]. While a timely diagnosis of central nervous system (CNS) infections is critical, ruling out infection can impact patient care, including reducing healthcare cost, length of stay, extended and unnecessary antimicrobial therapy, and procedures [5, 12].

Currently, there are no published guidelines regarding indications for the use of the ME panel or interpretation of results. Patients with suspected meningitis and encephalitis are cared for by various subspecialties, including but not limited to, Pediatric Hospital Medicine (PHM), Pediatric Emergency Medicine (PEM), Pediatric Infectious Diseases (ID), and Pediatric Intensive Care Unit (PICU) physicians through the course of illness. Little is known about the current state of use of the panel in the U.S. and the practice variation among institutions and sub-specialties. Practice variation occurs when there is uncertainty in diagnosis/management, and no clear evidence or guidelines exist. Recognizing that variation exists is the first step in standardizing the best practice of how the ME panel should be used.

The purpose of this study was to evaluate the current use of ME panel and to explore provider and subspecialty practice variation in its use.

Methods

The study was approved by the Institutional Review Board at the Akron Children’s Hospital, Akron, Ohio, USA. We performed an online cross-sectional survey of PHM, PEM, and PICU physicians between August-September of 2019. The survey was created by an iterative process among physicians from the above-mentioned specialties with additional input from ID physicians. The survey was pilot tested among 50 PHM providers and adjustments made to improve the questions’ clarity. The final survey consisted of 14 items, including demographic information and two specific clinical scenarios (supplemental file) and was created on Institutional Research Electronic Data Capture (REDCap). The survey was distributed through the American Academy of Pediatrics Section on Hospital Medicine (AAP-SOHM) (4074 subscribers), Brown University PEM (2724 subscribers), and PICU virtual pediatric system (VPS) (200 PICU’s with one contact person at each site) listservs. The AAP-SOHM listserv is sponsored by the AAP and is targeted to pediatric hospitalists. The Brown University PEM listserv is sponsored by Brown University, but targets PEM providers around the country. The PICU VPS listserv represents 200 PICU’s. In total, we estimate that there are 6998 subscribers to these listservs. However, there are frequent changes to subscribers and, therefore, total numbers are hard to definitively identify. Providers subscribed to these listservs above received an email with a unique online survey from REDCap. Reminder emails were sent out twice, 2-weeks apart. An opportunity to enter a raffle to win one of four $25 gift cards was provided to increase survey response rates.

Statistical analysis was performed using SAS (version 9.4; SAS Institute Inc., Cary, NC, USA). Descriptive statistics were used as appropriate. Chi-square test and/or Fisher’s exact tests were used to compare categorical variables. All tests were two-sided, and P-value less than 0.05 was considered significant.

Results

Participants characteristics

A total of 335 providers (4.8% response rate) from 40 states and 177 hospitals responded to the survey (Fig. 1). Four providers did not complete the entire survey and were excluded from the final count of 331 responses. Sixty-five providers did not identify their hospital on the survey. There were 169 PHM, 130 PEM, 19 PICU, 4 ID, and 1 NICU providers who responded to this survey. The majority of respondents were PHM providers (n=169, 51%), worked in a university-affiliated children’s hospital
(n=193, 58%), and 39% (n=56) were in practice for more than 10 years (Table 1). Of the two-hundred twenty-six providers who used the ME panel, 58% self-reported a lack of knowledge of performance characteristic of the ME panel. In terms of ability to interpret the test results, 71% (159/226) self-reported being confident or very confident in interpreting the test result.

Current use of ME panel
Most participants (68%, 226/331) reported using the ME panel at their institution with fewer (8%, 28/331) using the test for more than four years. Among those who use the ME panel, 4% reported still using a single organism PCR test in all scenarios, 55% reported using it in some scenarios and 40% reported that they no longer use a single organism PCR test. 52% (116/226) reported that the result was available in <3 h, with most (78%) reporting that results were available within 6 h. A prolonged test result time was statistically associated with the test being performed as a send-out from the institution (p=0.001).

Availability of guidelines
Among those using the panel, 75% (171/226) and 76% (173/226) of respondents reported not having institutional guidelines about utilization and interpretation of ME panel results, respectively (Table 2). There was no difference noted between free-standing children’s hospitals and community hospitals in terms of availability of guidelines (24% vs. 21%; p=0.62). Similarly, no difference was noted with university affiliation in terms of providing guidelines for ordering and interpreting results (17% vs. 26%; p=0.15). A subset analysis was done between providers from institutions that provided guidelines and those that did not. Providers from institutions that provided guidelines self-reported higher knowledge of test performance characteristics as compared to those that did not (51% vs. 38%; p=0.01). There was no difference in reported confidence in interpreting ME panel results between these two groups (p=0.09). No difference was noted in terms of starting, stopping, or narrowing antibiotics (p=0.22; p=0.36; p=0.70), respectively, between these two groups.

Clinical scenarios
Analysis of clinical case scenarios (Table 2) revealed that 188/226 (83%) providers would start antibiotics in a 4-year old with a positive bacterial ME panel result even if clinical features are not consistent with meningitis. This response increased to 95% when a “CSF cell count suggestive of meningitis” was provided (Table 2). In this same scenario with “cell count suggestive of meningitis”, 45% reported that they would narrow the antibiotics based upon the meningitis/encephalitis panel result without waiting for cultures. In a 3-week old febrile infant whose clinical picture is not consistent with bacterial meningitis, 82/226 (36%) of providers reported that they would
stop antibiotics based on the sole presence of positive viral pathogen obtained via the ME panel. Among those who responded they would not stop antibiotics, 29/144 (21%) reported they would stop antibiotics when provided with “normal CSF cell counts”.

Subspecialty analysis
A subset analysis was done between PHM and PEM providers to evaluate for differences between the two groups. This analysis was not performed on PICU providers given the low number of participants from PICU. 48% (61/128) of PHM providers report being aware of the performance characteristic of the ME panel compared to 27% (21/77) of PEM physicians (p = 0.004) (Table 2). There was no difference in reported confidence in interpreting ME panel results between the two groups (p = 0.8). No difference was noted in terms of starting, stopping, or narrowing antibiotics (p = 0.21; p = 0.18; p = 0.15), respectively, between PHM and PEM physicians in the provided clinical scenarios.

Discussion
This study provides an overview of the ME panel’s current use among pediatric providers in the U.S and highlights the variation in its use and interpretation. 68% of respondents in our survey use the ME panel, but only 25% are aware of ordering guidelines, and 26% have institutional guidelines directing its interpretation. A majority of participants still reported using single organism PCR in addition to the ME panel.

When a new diagnostic test is being introduced, it is imperative that there be clear guidelines on test indications/interpretation, evaluation of the cost-benefit ratio, and an ongoing assessment of the risks and benefits of the test. With the easy availability of the CSF ME panel, overutilization has been noted, with the test being performed in patients with little or no suspicion of CNS infection [13–15]. Furthermore, use of a single organism PCR in addition to the ME panel may add to healthcare costs without providing additional diagnostic information. Although, there may be times where this is necessary, such as HSV PCR testing when this diagnosis is highly suspected, but the ME panel is negative. Test overuse causes unnecessary costs and may also lead to incorrect diagnosis and inappropriate treatment. Though less than half of the providers in our survey report being aware of test performance characteristics, the majority reported confidence in interpreting the results. This may further point to overconfidence bias, a known cognitive bias associated with diagnostic inaccuracies and suboptimal management [16]. Increasing providers’ knowledge and providing tools like practice guidelines, diagnostic stewardship, and clinical algorithms are paramount in successfully implementing new testing method. Pairing antimicrobial stewardship with novel diagnostic tools is well-studied in the literature, including blood culture and MEP interpretation. In both instances, introduction of test use guidelines, audit and feedback, and interpretation guidance was associated with decreased antimicrobial use, ancillary testing, and increased antibiotic de-escalation [17, 18]. In the ME panel’s case, these tools ensure maximum clinical benefit (avoid unnecessary antimicrobials, reduce the length of stay, and avoid unnecessary diagnostic tests) without test overuse, inappropriate treatment, and overburdening the health care economy.

In our survey, providers were more likely to start antibiotics in the presence of a positive bacterial ME panel test; however, they hesitated to stop antibiotics with a negative bacterial ME test or with the detection of a

| Table 1 Demographics of the survey respondents |
|-----------------------------------------------|
| Characteristics of hospital                    |
| Children’s hospital - Not university affiliated | 46  13.9 |
| Children’s hospital - University affiliated    | 193 58.3 |
| Community hospital - Not university hospital  | 36  10.8 |
| Community hospital - University affiliated    | 41  12.3 |
| Others                                        | 15  4.53 |
| Location                                      |
| Outside United states                         | 3   0.91 |
| US-Midwest                                    | 108 32.6 |
| US-Northeast                                  | 81  24.4 |
| US-West coast                                 | 47  14.2 |
| US-South                                      | 92  27.7 |
| Your current position                         |
| Physician (MD/DO)                             | 320 97.5 |
| Advance practice provider                     | 8   2.4 |
| No answer                                     | 3   |
| Years in practice                             |
| In-Training                                   | 20  6.0 |
| 1–2 years                                     | 51  15.4 |
| 3–5 years                                     | 73  22.1 |
| 6–10 years                                    | 56  16.9 |
| 10+ years                                     | 130 39.3 |
| No answer                                     | 1   |
| Sub-specialty                                 |
| PHM                                           | 169 51.2 |
| PEM                                           | 130 39.3 |
| PICU                                          | 19  5.7 |
| ID                                            | 4   1.2 |
| NICU                                          | 1   0.3 |
| Others                                        | 8   2.1 |

Abbreviations: PHM, pediatric hospital medicine; PEM, pediatric emergency medicine; PICU, pediatric critical care unit; ID, infectious disease; NICU, neonatal intensive care unit
Similarly, less than half of the respondents reported confidence in narrowing the antibiotics based on ME panel results. Potential reasons could include a lack of knowledge and understanding of multiplex PCR by providers and/or concern for false negatives. The ME panel has a sensitivity of 90% and specificity of 98%; however, a small number of false positives and false negatives are reported with the test [19]. These findings suggest that providers’ hesitancy to discontinue antibiotics may in part be due to a lack of knowledge about ME Panel test performance. However, other factors may certainly influence these decisions, including provider awareness/confidence.

Table 2: Responses to institutional and personal awareness/confidence questions, in addition to responses to clinical case scenarios

| Question                                                                 | Total        | Specialty     | P         |
|-------------------------------------------------------------------------|--------------|---------------|-----------|
| Are you aware of any institutional guidelines regarding the use (ordering) of CSF BioFire® testing? | -            | -             | 0.2585    |
| Yes                                                                     | 55 (24.3)    | 35 (27.3)     | 14 (18.0) | 6 (30.0) |
| No                                                                      | 171 (75.7)   | 93 (72.7)     | 64 (82.0) | 14 (70.0) |
| Does your institution provide guidelines for interpreting CSF BioFire® results? | -            | -             | 0.582     |
| Yes                                                                     | 53 (23.5)    | 27 (21.1)     | 20 (25.6) | 6 (30.0) |
| No                                                                      | 173 (76.5)   | 101 (78.9)    | 58 (74.4) | 14 (70.0) |
| Are you aware of the performance characteristics (sensitivity/specificity/positive predictive value/negative predictive value) of the CSF BioFire® test? | -            | -             | 0.0366    |
| Yes                                                                     | 36 (16.0)    | 23 (18.0)     | 8 (10.4)  | 5 (25.0) |
| No                                                                      | 132 (58.7)   | 67 (52.3)     | 56 (72.7) | 9 (45.0) |
| On a scale of 1 to 5, with 5 being VERY confident, how confident are you in interpreting the results of the CSF BioFire® test? | -            | -             | 0.9394    |
| Very confident                                                          | 36 (16.1)    | 19 (15.1)     | 13 (16.9) | 4 (20.0) |
| Confident                                                               | 123 (55.1)   | 72 (57.1)     | 40 (52.0) | 11 (55.0) |
| Somewhat confident                                                      | 54 (24.2)    | 30 (23.8)     | 19 (24.7) | 5 (25.0) |
| Not confident                                                           | 10 (4.5)     | 5 (4.0)       | 5 (6.5)   | 0        |
| Unable to interpret                                                     | 0 (0)        | 0             | 0         | 0        |
| An otherwise healthy 4 year old patient presents with fever and headache. His clinical features are not suspicious of bacterial meningitis/encephalitis; however, an LP is done and the CSF bacterial BioFire® results are positive for a bacterial pathogen. Would you start antimicrobials based on positive CSF bacterial BioFire® results alone? | -            | -             | 0.4466    |
| Yes                                                                     | 188 (83.1)   | 103 (81.5)    | 68 (87.2) | 17 (85.0) |
| No                                                                      | 38 (16.8)    | 25 (19.5)     | 10 (12.8) | 3 (15.0) |
| If no, would you start antimicrobials based on positive CSF bacterial BioFire® results in addition to CSF cell count suggestive of meningitis? | -            | -             | 0.0043    |
| Yes                                                                     | 36 (94.7)    | 25 (100.0)    | 10 (100.0)| 1 (33.3) |
| No                                                                      | 2 (5.2)      | 0             | 0         | 2 (66.7) |
| In the same patient, would you narrow the antibiotics given the positive bacterial BioFire® test without waiting for culture? | -            | -             | 0.291     |
| Yes                                                                     | 87 (45.5)    | 42 (40.4)     | 36 (51.4) | 9 (52.9) |
| No                                                                      | 104 (54.4)   | 62 (59.6)     | 345 (48.6)| 8 (47.1) |
| On a 3-week-old febrile infant whose clinical picture is not consistent with bacterial meningitis, would you stop antimicrobials based on positive viral (ex: enterovirus) BioFire® results alone? | -            | -             | 0.4185    |
| Yes                                                                     | 82 (36.2)    | 51 (39.8)     | 24 (30.8) | 7 (35.0) |
| No                                                                      | 144 (63.7)   | 77 (60.2)     | 54 (69.2) | 13 (65.0) |
| If no, would you stop antibiotics based on a negative bacterial BioFire® result and normal CSF cell counts without waiting for culture? | -            | -             | 0.9182    |
| Yes                                                                     | 29 (20.5)    | 16 (21.3)     | 10 (18.9) | 3 (23.1) |
| No                                                                      | 112 (79.4)   | 59 (78.7)     | 43 (81.1) | 10 (76.9) |

Abbreviations: LP, lumbar puncture; CSF, cerebrospinal fluid
experience, pre-test probability, or suspicion for organisms not detected on the ME panel given the clinical scenario. The hesitation in discontinuing antibiotics is in concordance with other studies where physicians start antibiotics more often with a negative viral test but only occasionally stop antibiotics in the presence of viral pathogen [20]. A prior study found that implementation of interpretation guidance for enterovirus testing results was associated with decreased antibiotic use in febrile infants found to have enterovirus meningitis [21]. Similarly, our study results indicate that there is likely an opportunity to provide interpretation guidance and information about ME Panel test performance characteristics to help inform clinical decision making. Inclusion of such tools with diagnostic and antimicrobial stewardship may help achieve desired clinical outcomes. As such, there is a clear role for clinical microbiology laboratory and antimicrobial stewardship teams to work together to develop test use and interpretation guidance to avoid unnecessary antibiotic use. These clinical guidelines or pathways as part of an antimicrobial stewardship team may help provide support to clinicians, especially with patient populations where management can be less straightforward, as is frequently encountered with infants<2 months old and patients with positive viral targets of unclear significance, such as HHV-6. Studies evaluating such stewardship programs (including use of real-time decision support) indicate potentially positive effects on length of empiric antibiotic and ancillary test utilization [22, 23].

In our study, PHM providers were more aware of the test characteristics compared to PEM providers. This could be attributed to the fact that continuing, narrowing, and stopping antimicrobials falls under the hospitalist realm of practice; thus, they are required to be more knowledgeable. The context in which these two subspecialists encounter a suspected ME patient is also different. Hospitalists have the benefit of observing patients over the clinical course, whereas a PEM provider has the advantage of assessing patients firsthand. Though our study did not find a difference in clinical management between these two subspecialties, further analysis inclusive of subspecialties like ID and PICU is needed to fully elucidate variability. The inclusion of all providers from various specialties involved in the continuum of care is essential while developing clinical tools.

Our study has several limitations. We estimated the number of emails subscribed to the listserves; however, the exact denominator within each listservce changes frequently. Therefore, this might not be an accurate representation of all providers. Our study also has a lower response rate of 4.8% than the average listserv response rate of 8–20% [24–26]. We could not account for potential differences in non-responders to know if our sample represents physicians at large. Furthermore, multiple providers may have responded from a single institution, which may over- or under-represent certain institutional practice. However, we believe this finding highlights intra-institutional practice variation and an opportunity for practice standardization. The high percentage of respondents who reported using the ME panel in our study also raises concern for bias, as people who use the ME panel were more likely to respond to the survey. We only used two specific clinical scenarios on the survey questions with limited information and we did not allow for a free-text response. Thus, our results may not fully reflect what providers would do in real-life clinical scenarios where more clinical and supporting laboratory evidence would be available. The survey was not validated beyond pilot testing with PHM providers, limiting its applicability to PEM and PICU providers. Our clinical vignettes did not specify which bacterial and viral targets were identified, which may have contributed to response variability. Lastly, most of the respondents in our survey were PHM and PEM physicians with limited response from PICU physicians, making the results less generalizable to intensivists. In general, PHM physicians were overrepresented in our sample with limited data from advanced practice providers, which limits generalizability of our study. Furthermore, very few ID physicians responded, and thus our results may not represent practice standards of this subspecialty. However, ID physicians frequently play an important role in clinical decision making in these patients. Despite these limitations, our study provides a good starting point for future research on guideline development for the ME panel and identifies areas for provider education. Comparative analysis of institutions and subspecialty based on the presence or absence of rigorously developed evidence-based guidelines focusing on clinical outcomes and missed diagnosis may provide an answer to this in the future.

Conclusion

The optimal impact of new diagnostic tools on patient outcomes requires provider education, practice guidelines, and continuous review and feedback. Our study identifies a knowledge gap in these areas for ME panel test. The majority of providers in our study were not aware of guidelines regarding the ME panel test. We did not notice a significant difference between PHM and PEM physicians in clinical management based on ME panel results; however further research is needed to fully evaluate ME panel use variability.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07789-2.
**Acknowledgements**

The authors would like to thank Dr. Carrie Hemmer, MD and Dr. Eric Robinette, MD for their contribution.

**Authors’ contributions**

Dr. Rajbhandari, Nabower, and Snowden conceptualized the study and primarily participated in its design and data collection/interpretation. Dr. Rajbhandari drafted the original manuscript, participated in its editing, and gave final approval to the submitted manuscript. Drs. Goodrich, Nabower, Brown, Ekambaram, Eisenberg, Forbes, Gollehon, Martin, McCulloh, and Stone gave approval to the study design, assisted in data interpretation, and participated in the revision, editing, and approval of the manuscript and its revisions, as submitted. Dr. Goodrich organized the revision of the original manuscript and approved its final version, as submitted.

**Funding**

The gift cards were funded by a Pediatric Research grant from the Child Health Research Institute at UNMC/Children’s Hospital & Medical Center ($15558 total funding).

**Data availability**

The datasets generated and/or analyzed during the current study are not publicly available. Per a data sharing agreement, deidentified individual participant data cannot be made available. However, data are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all subjects and/or their legal guardian(s). The study was approved by the Institutional Review Board of Akron Children’s Hospital.

**Consent for publication**

Not applicable.

**Competing interests/financial disclosure**

Dr McCulloh receives support from the Office of the Director of the National Institutes of Health under award UG1OD024953. Funded by the National Institutes of Health (NIH). Dr McCulloh from time to time provides advice on legal matters. No other authors have competing interests or financial disclosures. The other authors have no disclosures.

**Received: 17 November 2021 / Accepted: 18 October 2022**

**Published online: 31 October 2022**

**References**

1. Bagdure D, Custer JW, Rao S, et al. Hospitalized Children With Encephalitis in the United States: A Pediatric Health Information System Database Study. Pediatr Neurol. 2016;61:58–62.

2. Balada-Llasat JM, Rosenthal N, Hasbun R, et al. Cost of managing meningoencephalitis among infants and children in the United States. Diagn Microbiol Infect Dis. 2019;93(4):349–54.

3. FDA allows marketing of the first nucleic acid-based test to detect multiple pathogens from a single sample of cerebrospinal fluid. October 8, 2015. https://www.infectioncontroltoday.com/fda/fda-approves-market-first-nucleic-acid-based-test-detect-multiple-pathogens-csf. Published 2015. Accessed 4/2/2020, 2020.

4. The BioFire FilmArray Meningitis/Encephalitis(ME) Panel. https://www.biofiredx.com/products/thefilmarray-panels/filmarraymme/. Accessed 3/31/2020, 2020.

5. O’Brien MP, Francis JR, Marr IM, Baird RW. Impact of Cerebrospinal Fluid Multiplex Assay on Diagnosis and Outcomes of Central Nervous System Infections in Children: A Before and After Cohort Study. Pediatr Infect Dis J. 2018;37(9):888–71.

6. Leber AL, Everhart K, Balada-Llasat JM, et al. Multi-center Evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for Detection of Bacterial, Viruses, and Yeast in Cerebrospinal Fluid Specimens. J Clin Microbiol. 2016;54(9):2251–61.

7. Arora HS, Asmar Bi, Salimiena H, Agraval P, Chawla S, Abul-Haq N. Enhanced Identification of Group B Streptococci and Escherichia Coli in Young Infants with Meningitis Using the BioFire Filmarray Meningitis/Encephalitis Panel. Pediatr Infect Dis J. 2017;36(7):685–7.

8. Welnder-Olsson C, Dotellli V, Hogevik H, et al. Comparison of broad-range bacterial PCR and culture of cerebrospinal fluid for diagnosis of community-acquired bacterial meningitis. Clin Microbiol Infect. 2007;13(9):879–86.

9. Sigfrid L, Perfect C, Rojek A, et al. A systematic review of clinical guidelines on the management of acute, community-acquired CNS infections. BMC Med. 2019;17(1):170.

10. Posadas E, Fisher J. Pediatric bacterial meningitis: an update on early identification and management. Pediatr Emerg Med Pract. 2018;15(11):1–20.

11. Costa BND, Sato DR. Viral encephalitis: a practical review on diagnostic approach and treatment. J Pediatr (Rio J). 2020;96(Suppl 1):12–9.

12. Nabower AM, Miller S, Biwer B, et al. Association of the FilmArray Meningitis/Encephalitis Panel With Clinical Management. Hosp Pediatr. 2019;9(10):763–9.

13. Radmard S, Reid S, Ciyam P, et al. Clinical Utilization of the FilmArray Meningitis/Encephalitis (ME) Multiplex Polymerase Chain Reaction (PCR) Assay. Front Neurol. 2019;10:281.

14. Eichinger A, Hagen A, Meyer-Buhn M, Huebner J. Clinical benefits of introducing real-time multiplex PCR for cerebrospinal fluid as routine diagnostic at a tertiary pediatric care center. Infection. 2019;47(1):51–8.

15. Naccache SN, Lustestica M, Fahit M, Mestas J, Dien Bard J. One Year in the Life of a Rapid Syndromic Panel for Meningitis/Encephalitis: a Pediatric Tertiary Care Facility’s Experience. J Clin Microbiol. 2018;56(3).

16. Saposnik G, Redelmeier D, Ruff CC, Tobler PN. Cognitive biases associated with medical decisions: a systematic review. BMC Med Inform Decis Mak. 2016;16(1):138.

17. Crook J, Xu M, Slaughter JC, Willis J, Browning W, Estrada C, et al. Impact of clinical guidance and rapid molecular pathogen detection on evaluation and outcomes of febrile or hypotensive infants. Infect Control Hosp Epidemiol. 2020;41(1):1285–91.

18. Banerjee R, Teng CB, Cunningham SA, Ihde SM, Stockelberg JM, Moriarty JP, et al. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. 2015;61(7):1071–80.

19. Tansari GS, Chapin KC. Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26(3):281–90.

20. McCulloh RJ, Andrea S, Reinert S, Chapin K. Potential Utility of Multiplex Amplification Respiratory Viral Panel Testing in the Management of Acute Respiratory Infection in Children: A Retrospective Analysis. J Pediatr Infect Dis Soc. 2014;3(2):146–53.

21. DeFerre A, Williams CD, Schuster J, et al. Evaluating the Impact of Implementing a Clinical Practice Guideline for Febrile Infants With Positive Respiratory Syncytial Virus or Enterovirus Testing. Hosp Pediatr. 2017;7(10):587–94.

22. Messacar K, Palmer C, Greigore L, Elliott A, Ackley E, Perraillon MC, et al. Clinical and Financial Impact of a Diagnostic Stewardship Program for Children with Suspected Central Nervous System Infection. J Hosp Pediatr. 2022;244:161–8.

23. Crook J, Xu M, Slaughter JC, Willis J, Browning W, Estrada C, et al. Impact of clinical guidance and rapid molecular pathogen detection on evaluation and outcomes of febrile hypotensive infants. Infect Control Hosp Epidemiol. 2020;41(1):1285–91.

24. Adame N, Rocha ME, Louden C, Agrawal R. Pediatric hospitalists’ perspectives on the care of children with medical complexity. Hosp Pediatr. 2011;1(1):30–7.

25. Hall AM, Ayus J, Moritz ML. How Salty Are Your Fluids? Pediatric Main Journalist’s Role? An exploratory survey of current attitudes. J Hosp Med. 2019;7:549.

26. Collins SW, Reiss J, Saidi A. Transition of care: what is the pediatric hospitalist’s role? An exploratory survey of current attitudes. J Hosp Med. 2012;7(6):277–81.

**Publisher’s note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.